Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a tetracyclic antidepressant presented as an oral tablet for oral use. It works by enhancing norepinephrine and serotonin transmission and is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for mental health care. The company adheres to stringent manufacturing standards and ensures consistent product quality across global markets.

Mirtazapine is indicated for depressive disorders and related conditions.

Major depressive disorder: alleviates depressive symptoms and improves mood in adults. Depressive episodes with anxiety: reduces anxiety components associated with depression. Depression with insomnia: promotes sleep while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions, varying from common to rare but serious.

Common Side Effects: - Drowsiness or sedation - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic dysfunction (elevated liver enzymes, hepatitis) - Severe hypersensitivity reactions (rash, Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Cardiovascular events such as arrhythmia

When prescribing Mirzaten, clinicians should consider several safety measures.

Dose titration: start with low dose and increase gradually under medical supervision. Monitor weight: watch for significant weight gain during therapy. Assess hepatic function: use caution in patients with liver impairment. Avoid abrupt discontinuation: taper dose to prevent withdrawal symptoms. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Mirtazapine can interact with a variety of medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; ensure a 14‑day washout. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma levels. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - Anticholinergic drugs: may exacerbate dry mouth. - Warfarin: monitor INR as interaction possible.